株探米国株
英語
エドガーで原本を確認する
6-K 1 rdy0775_6k.htm FORM 6-K
 

 

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

Form 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

July 2025

 

Commission File Number 1-15182

 

DR. REDDY’S LABORATORIES LIMITED

(Translation of registrant’s name into English)

 

8-2-337, Road No. 3, Banjara Hills

Hyderabad, Telangana 500 034, India

+91-40-49002900

 

(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

 

Form 20-F  x                               Form 40-F   ¨

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ______

 

Note:  Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted solely to provide an attached annual report to security holders.

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ______

 

Note:  Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated, domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.

 

Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

 

Yes  ¨                                     No   x

 

If “Yes” is marked, indicate below the file number assigned to registrant in connection with Rule 12g3-2(b): 82-________.


 

 

EXHIBITS

 

Exhibit
Number

 

Description of Exhibits

 

 

 

99.1


Intimation dated July 15, 2025

 

2

 

SIGNATURES


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

 

DR. REDDY’S LABORATORIES LIMITED

(Registrant)

 

 

 

Date: July 15, 2025   

By:  

/s/ K Randhir Singh

 

 

Name:  

K Randhir Singh

 

 

Title:  

Company Secretary


3


EX-99.1 2 rdy0775_ex99-1.htm EXHIBIT 99-1

 

Exhibit 99.1

 

Dr. Reddy's Laboratories Ltd.

8-2-337, Road No. 3, Banjara Hills

Hyderabad – 500 034, Telangana, India

 

CIN: L85195TG1984PLC004507

 

Tel:       + 91 40 4900 2900

Fax:     + 91 40 4900 2999

Email: mail@drreddys.com

Web:   www.drreddys.com

 

July 15, 2025

 

National Stock Exchange of India Ltd. (Stock Code: DRREDDY)

BSE Limited (Stock Code: 500124)

New York Stock Exchange Inc. (Stock Code: RDY)

NSE IFSC Ltd. (Stock Code: DRREDDY)

 

Dear Sir/ Madam,

 

Sub: Intimation of Earnings call

 

Please find enclosed a notification titled “Dr. Reddy's to release Q1FY26 results on Wednesday, July 23rd, 2025; Earnings call slated for Wednesday, July 23rd @19:30 PM IST / 10:00 AM ET

 

This is for your information and records.

 

Thanking you.

 

Yours faithfully,

For Dr. Reddy’s Laboratories Limited


K Randhir Singh

Company Secretary, Compliance Officer & Head-CSR Dr. Reddy's to release Q1FY26 results on Wednesday, July 23rd, 2025; Earnings call slated for Wednesday, July 23rd @19:30 PM IST / 10:00 AM ET

 

 



DR. REDDY'S LABORATORIES LTD.

8-2-337, Road No. 3, Banjara Hills,

Hyderabad - 500034, Telangana, India.

CONTACT

INVESTOR RELATIONS

MEDIA RELATIONS

RICHA PERIWAL richaperiwal@drreddys.com

AISHWARYA SITHARAM aishwaryasitharam@drreddys.com

PRIYA K

priyak@drreddys.com


 



 


Hyderabad, India, July 15th, 2025

 

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY) will announce results for the quarter ended June 30th, 2025 on Wednesday, July 23rd, 2025 after the Board Meeting.

 

Summary of Events

 

Event

Date and Time

Medium

Release of financial results

July 23rd, 2025, after the Board Meeting

Stock Exchange, Media, Company Website, Email

Press Meet Presentation

Will be available on the Company’s Website

Company’s Website www.drreddys.com

Earnings Call

July 23rd, 19:30 PM IST / 10:00 AM

ET

Hosted by the Company (Details below)

Audio as well as Transcript of the Earnings call

Will be available on the Company’s Website

Company’s Website www.drreddys.com

 

Earnings Call

 

Following the release, the management of the Company will host its earnings call to discuss the Company’s financial performance.

 

Pre-register with the link below:


https://drreddys.zoom.us/webinar/register/WN RA32U4QvSCyTsyQgWVgrDA